Insider buying last 90 days
No open-market insider purchases were filed for DXCM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DXCM insider filing, plotted on the chart in Gekko.Open DXCM in Gekko
NASDAQ: DXCM
DexCom (DXCM) Stock Analysis & Forecast
Nov 4 close
$88.48+5.51 (+6.6%)
Gekko Brief
AI summaryNov 4 closeDexCom shares jumped this week after election results confirmed Democrats reclaimed majorities in the House and Senate, a move that lifted shares alongside peers like Align Technology and STERIS. Separately, DexCom announced it will launch its 15-Day G7 Continuous Glucose Monitoring System in Canada this November, extending sensor wear to up to 15.5 days with improved accuracy. The company is also navigating a planned Medicare expansion of device coverage for Type 2 diabetes patients not on insulin, alongside Abbott, as both companies adjust to shifting insurance and pricing dynamics. Separately, former CEO Kevin Sayer, now DexCom's Executive Chairman, was named to Guardant Health's board.
DXCM closed at $88.48, up 6.6%, sitting above both its 50-day ($85.49) and 200-day ($74.79) moving averages, with the 50-day above the 200-day. The GekkoIndex reads 53, placing the stock in the Neutral zone, though the index has fallen 14.3% over the past 5 sessions. Price sits 20.8% above Gekko Fair Value of $73.23, a gap that stands out against the recent rally.
The next earnings date falls on 11 February 2027, outside the typical 20-trading-day window. Over the last 30 days, one unusual options signal was recorded, with put premium of $555,108 exceeding call premium of $345,280. One billionaire holder is noted in recent filings. Seasonally, the next 20 trading days have averaged a 5.5% return over 5 years, with gains in 4 of those years. Analyst consensus from 17 firms shows 16 buy ratings and a target of $98.15.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
DexCom price vs fair value
Close $88.48200-day averageGekko Fair Value $73.23
DexCom quick facts
- Market cap
- $33.00B
- P/E ratio
- 33.4
- Forward P/E
- 26.5
- EPS, TTM
- $2.54
- Revenue, TTM
- $5.10B
- Profit margin
- 19.4%
- Dividend yield
- —
- Beta
- 1.44
- Volume
- 4.82M avg 4.90M
- 1-year return
- +46.4%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±7.2%
- 50-day average
- $85.49
- 200-day average
- $74.79
- Next earnings
- Feb 11 after close
- Shares outstanding
- 373.0M
DexCom swing-trade checklist
DexCom scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $88.48 is above the 50-day ($85.49) and 200-day ($74.79) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
53, Neutral
Reading 53 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
20.8% above
Price is 20.8% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 98 days
Next report Feb 11, 2027, 98 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.5% on average
From this point in the calendar, the next 20 trading days averaged +5.5% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
DexCom stock chart and price history
DexCom closed at $88.48 on Nov 4, 2026, +46.4% over the past year, inside a 52-week range of $54.11 to $92.59.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +6.1%
- 3 months
- +6.6%
- 6 months
- +46.6%
- 1 year
- +46.4%
The full DXCM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DXCM in Gekko
Follow DexCom through every session
Put DXCM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DXCM in GekkoFree for 7 days. No credit card required.
About DexCom
DexCom makes continuous glucose monitoring systems for people living with diabetes, along with tools that let doctors and other clinicians track that data. The company's devices are meant to replace routine finger-prick testing, giving users an ongoing read on glucose levels rather than a single snapshot. Its current lineup includes the G6 system, the newer Dexcom ONE, and a remote monitoring feature called Dexcom Share, with a next-generation G7 device in development.
Beyond its own hardware, DexCom offers a Real-Time API that lets outside developers build its glucose data into other health apps, and it has a licensing arrangement with Verily Life Sciences and Verily Ireland to work on further glucose monitoring products. Sales run directly to clinical specialists, including endocrinologists, physicians, and diabetes educators, who work with patients on managing the condition. The company serves markets both within the United States and abroad.
DexCom was started in 1999 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker DXCM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- dexcom.com
DexCom GekkoIndex: the smart money zone
DexCom’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53, in the Neutral zone, down 14.3 points over five sessions.
53Neutral
Down 14.3 points over five sessions, from the Accumulation zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 51 | +2.2% | +4.5% | ||
| Accumulation | 269 | −0.4% | −0.9% | ||
| Neutral (current zone) | 350 | −0.3% | −0.6% | ||
| Distribution | 22 | +0.3% | −0.4% | ||
| Selling | 5 | Too few readings yet | |||
Average DXCM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the DXCM price, zone by zone.Track DXCM in Gekko
Is DexCom stock overvalued? Gekko Fair Value
DexCom trades 20.8% above Gekko Fair Value of $73.23, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what DexCom shares are worth, recalculated every trading day.
$73.23
Gekko Fair Value, Nov 4, 2026
20.8% Overvalued
At the end of Aug 2026 the price was 26.8% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open DXCM in Gekko
DexCom insider and Congress trading
No open-market insider purchases were filed for DexCom, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DXCM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DXCM, plotted on the chart in Gekko.Open DXCM in Gekko
Buybacks
DexCom has been buying back its own shares.
- Latest authorization
- $1.00B, Oct 29, 2026
- Bought back, quarter ended Sep 30, 2026
- $400.0M
- As a share of market cap
- 1.21%
- Trailing four quarters
- $1.35B
From company filings.
Unusual options activity last 30 days
1signal, 38% of the flagged premium in calls.
Latest: Bullish flow on Oct 28, $900K in unusual premium.
Hedge funds and billionaires quarter ended Dec 31
1of the funds Gekko tracks holds DXCM.
1added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
DexCom earnings: next date and track record
DexCom reports on Feb 11, 2027, after the close (98 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Feb 11, 2027
Expected after the close, 98 days away
- EPS estimate
- $0.71
- Revenue estimate
- $1.38B
6 of 8reports beat the EPS estimate
±8.7%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Dexcom reported Q3 2026 revenue growth of 11% year-over-year on both reported and organic basis, with U.S. revenue up 14%. The company gained market share for multiple consecutive quarters, with strongest growth from Type 2 non-insulin diabetics. Their CONNECT randomized controlled trial showed 1.6% A1c improvement and was published in the New England Journal of Medicine, bolstering the case for CMS reimbursement expansion.
- Guidance
- Management expects CMS to announce a Type 2 non-insulin CGM coverage decision in 2026, which would significantly expand addressable market. The company anticipates continued low double-digit revenue growth with active patient base growing above that rate.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $0.73 est $0.68 | $1.34B est $1.33B | +4.7% |
| Jul 30, 2026 | $0.70 est $0.61 | $1.31B est $1.29B | +11.1% |
| Apr 30, 2026 | $0.56 est $0.47 | $1.19B est $1.17B | +6.6% |
| Feb 12, 2026 | $0.68 est $0.65 | $1.26B est $1.25B | +2.7% |
| Oct 30, 2025 | $0.61 est $0.58 | $1.21B est $1.18B | −14.6% |
| Jul 30, 2025 | $0.48 est $0.44 | $1.16B est $1.12B | −9.6% |
| May 1, 2025 | $0.32 est $0.33 | $1.04B est $1.02B | +14.3% |
| Feb 13, 2025 | $0.45 est $0.48 | $1.11B est $1.11B | +6.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
DexCom stock forecast and analyst price targets
Analysts’ average 12-month price target for DexCom is $98.15, +10.9% from the last close, from 17 firms rating the stock in the last 90 days.
$98.15consensus 12-month target, +10.9% from the last close
Now $88.48Avg $98.15
Low $85High $120
Each firm’s latest rating in the last 90 days: 17 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Leerink Partners | $94 | +6.2% |
| Oct 30 | Piper Sandler | $95 | +7.4% |
| Oct 30 | UBS | $107 | +20.9% |
| Oct 30 | Evercore ISI | $110 | +24.3% |
| Oct 30 | TD Cowen | $95 | +7.4% |
−0.6%average 20-day move after past Neutral readings
+5.5%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
DexCom seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, DexCom averaged +5.5% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 3 of 5 |
| Next 10 trading days | +3.5% | 3 of 5 |
| Next 15 trading days | +4.3% | 3 of 5 |
| Next 20 trading days | +5.5% | 4 of 5 |
| Next 30 trading days | +6.3% | 3 of 5 |
For scale, DXCM’s typical 20-trading-day move in either direction is about 7.2%.
DexCom market cap and key statistics
DexCom’s market cap is $33.00B, with a P/E ratio of 33.4 and revenue of $5.10B over the last twelve months.
Valuation
- Market cap
- $33.00B
- P/E ratio
- 33.4
- Forward P/E
- 26.5
- EPS, TTM
- $2.54
- Gekko Fair Value
- $73.23
Trading
- Volume
- 4.82M
- Avg volume, 20 days
- 4.90M
- 52-week high
- $92.59
- 52-week low
- $54.11
- Shares outstanding
- 373.0M
Financials
- Revenue, TTM
- $5.10B
- Profit margin
- 19.4%
- Return on equity
- 37.7%
- Quarterly earnings growth, YoY
- +2.6%
Risk and income
- Beta
- 1.44
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±7.2%
DexCom stock news this week
Coverage of DexCom this week reads positive: 15 positive, 6 neutral and 0 negative headlines.
- AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to knowTradingView, Nov 4
- DexCom (DXCM) Stock Price, Chart & Analysiswww.debelegger.nl, Nov 4
- DexCom, Inc. (DXCM) Seasonal returns chart - Yahoo FinanceYahoo Finance Singapore, Nov 4
- Guardant Health adds former Dexcom CEO Kevin Sayer to its boardStreetInsider, Nov 3
- DexCom to Launch 15-Day G7 CGM System in Canada This NovemberTradingView, Nov 3
- DexCom, Inc. (DXCM.VI) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada, Nov 2
DexCom peers
DexCom’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
DexCom stock FAQ
What is DexCom’s market cap?
DexCom’s market cap is $33.00B at the Nov 4, 2026 close of $88.48, with 373.0M shares outstanding. The shares trade on a P/E ratio of 33.4.
What is the DexCom stock forecast?
The consensus analyst 12-month price target for DexCom is $98.15, +10.9% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is DexCom stock overvalued or undervalued?
On Gekko’s estimate DexCom is overvalued: the Nov 4, 2026 close of $88.48 is 20.8% above Gekko Fair Value of $73.23. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does DexCom report earnings next?
DexCom is expected to report on Feb 11, 2027, after the market closes (98 days away). Analysts expect earnings of $0.71 per share on revenue of $1.38B. DexCom beat the earnings estimate in 6 of its last 8 reports, moving 8.7% on average across the report.
What is DexCom’s 52-week high and low?
DexCom’s 52-week high is $92.59 and its 52-week low is $54.11; it closed at $88.48 on Nov 4, 2026, +46.4% over the past year. Over the last five years the shares peaked at $164.86 on Nov 18, 2021.
Is DexCom stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in DexCom?
Gekko flagged 1 unusual options signal in DexCom over the last 30 days, with $345K of flagged premium in calls and $555K in puts. The latest, bullish flow, was on Oct 28, 2026 with $900K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See DexCom the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.